M A Weiler - JoVE Visualize

Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Policies

Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Policies

Filters

M A Weiler

Showing results (11-20 of 16) with videos related to

Pageof 2

Sort By:

You have reached the last page of results.This site can display upto 16 results.

Biological Psychiatry|May 10, 2001

Long-term outcome of patients who receive ketamine during researchA C Lahti, D Warfel, T Michaelidis, et al.

Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology|September 15, 2001

Effects of ketamine in normal and schizophrenic volunteersA C Lahti, M A Weiler, B A Tamara Michaelidis, et al.

Psychiatric Journal of the University of Ottawa : Revue De Psychiatrie De L'Universite D'Ottawa|September 1, 1988

Panic disorder is borderline personality disorderM A Weiler, E R Val, M Gaviria, et al.

Biological Psychiatry|January 27, 1998

Antipsychotic properties of the partial dopamine agonist (-)-3-(3-hydroxyphenyl)-N-n-propylpiperidine(preclamol) in schizophreniaA C Lahti, M A Weiler, P K Corey, et al.

The American Journal of Psychiatry|November 3, 2001

Abnormal patterns of regional cerebral blood flow in schizophrenia with primary negative symptoms during an effortful auditory recognition taskA C Lahti, H H Holcomb, D R Medoff, et al.

Psychiatry Research|July 1, 1988

EEG sleep, lithium transport, dexamethasone suppression, and monoamine oxidase activity in borderline personality disorderH W Lahmeyer, E Val, F M Gaviria, et al.

Pageof 2

Search research articles

Showing results (11-20 of 16) with videos related to

Sort By:

Pageof 2

You have reached the last page of results.This site can display upto 16 results.

Biological Psychiatry|May 10, 2001

Long-term outcome of patients who receive ketamine during researchA C Lahti, D Warfel, T Michaelidis, et al.

Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology|September 15, 2001

Effects of ketamine in normal and schizophrenic volunteersA C Lahti, M A Weiler, B A Tamara Michaelidis, et al.

Psychiatric Journal of the University of Ottawa : Revue De Psychiatrie De L'Universite D'Ottawa|September 1, 1988

Panic disorder is borderline personality disorderM A Weiler, E R Val, M Gaviria, et al.

Biological Psychiatry|January 27, 1998

Antipsychotic properties of the partial dopamine agonist (-)-3-(3-hydroxyphenyl)-N-n-propylpiperidine(preclamol) in schizophreniaA C Lahti, M A Weiler, P K Corey, et al.

The American Journal of Psychiatry|November 3, 2001

Abnormal patterns of regional cerebral blood flow in schizophrenia with primary negative symptoms during an effortful auditory recognition taskA C Lahti, H H Holcomb, D R Medoff, et al.

Psychiatry Research|July 1, 1988

EEG sleep, lithium transport, dexamethasone suppression, and monoamine oxidase activity in borderline personality disorderH W Lahmeyer, E Val, F M Gaviria, et al.

Pageof 2